As of Mar 24
| +0.54 / +2.65%|
The 12 analysts offering 12-month price forecasts for Travere Therapeutics Inc have a median target of 36.50, with a high estimate of 52.00 and a low estimate of 17.00. The median estimate represents a +74.47% increase from the last price of 20.92.
The current consensus among 13 polled investment analysts is to Buy stock in Travere Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.